Organon jumps despite Q2 revenue dip as revised outlook exceeds consensus

15 hours ago 1

• Earnings News
• Healthcare
• On the Move

CharlieAJA/iStock via Getty Images

Organon (NYSE:OGN) traded ~6% higher in the premarket on Tuesday after the company raised its full-year outlook to a level above consensus following Q2 2025 financials, which also exceeded Street forecasts despite a slight revenue drop during the quarter.

The

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. Organon jumps despite Q2 revenue dip as revised outlook exceeds consensus